Endocrine Today Current Issue
The following articles appeared in the print edition of Endocrine Today.
Table of Contents
- Microbiome’s ‘untapped extra genome’ may hold clues to prevent, treat diabetes
-
- FDA approves nonadjunctive indication for Eversense CGM
- FDA approves Victoza for children with type 2 diabetes
- Adjunct therapies desired to reduce ‘constant daily burden’ of type 1 diabetes
- After 20-year increase, new diabetes cases decline 35%
- Fracture risk 73% higher after Roux-en-Y gastric bypass than adjustable gastric banding
- FRAX data suggest no increased fracture risk with aromatase inhibitor use
- High-activity radioiodine therapy acceptable for older adults with thyroid cancer
- ‘Substantial’ price increases continue for most popular brand-name drugs
-
- CARMELINA, CAROLINA shed new light on CV safety for linagliptin, glimepiride
- CREDENCE: Canagliflozin demonstrates CV, renal benefits in type 2 diabetes without CVD
- D2d: Vitamin D fails to prevent type 2 diabetes
- Diabetes coaching sparks HbA1c progress in pediatric type 1 diabetes
- ‘Medical bypass’ with triple gut-hormone infusion reduces glucose levels, body weight
- Personalized bionic pancreas increases time in range vs. usual care
- PIONEER: Oral semaglutide proves superior to empagliflozin, noninferior to liraglutide for lowering HbA1c
- PREVIEW: Intensive weight loss, behavior change prevents conversion to type 2 diabetes
-
- Teplizumab temporarily protects against type 1 diabetes in high-risk individuals
- Do genes or the environment play a bigger role in the development of type 2 diabetes?